MYOHMB-FA™ | Metabolite of leucine in the α-ketoisocaproate (KIC) pathway

1. Asset overview

MYOHMB-FA™ is an HMB-based asset (β-hydroxy-β-methylbutyrate free acid) developed as a platform to support muscle mass and function in adults, athletes, older adults, and selected clinical contexts characterized by muscle loss or high training load.

The program is structured as a technical development dossier (Wet-Lab + CMC + QbD), providing an integrated view from biological rationale to product engineering, analytical strategy, stability, safety, pilot human study, and regulatory route.

Table 1 – Asset overview

2. Biological rationale and functional target

MYOHMB-FA™ is centered on β-hydroxy-β-methylbutyrate (HMB), the principal metabolite of leucine in the α-ketoisocaproate (KIC) pathway.

Anabolic mechanism (↑ MPS)

Mechanistic data summarized in the dossier show that HMB:

• Stimulates muscle protein synthesis (MPS) with magnitude comparable to leucine;
• Activates the mTORC1 / p70S6K / 4E-BP1 pathway, increasing phosphorylation of key signaling proteins in skeletal muscle when HMB is combined with resistance exercise;
• Increases incorporation of labeled amino acids into myofibrillar proteins in human and animal models, especially under controlled anabolic stimuli.

Anticatabolic mechanism (↓ proteolysis)

HMB also acts as an anticatabolic agent by:

• Reducing expression of MuRF-1 and atrogin-1/MAFbx (E3 ubiquitin–proteasome ligases) in models of muscle atrophy;
• Modulating calpains and caspases involved in myofibrillar proteolysis;
• Attenuating inflammatory markers (IL-6, TNF-α) and muscle damage markers (CK) after intense exercise.

Clinical evidence in target populations

The dossier consolidates evidence that HMB supplementation at typical study doses:

• Improves or preserves muscle mass, strength and physical function in older adults and individuals with sarcopenia;
• Attenuates lean mass loss and, in some cases, improves functional outcomes in patients with cancer and other chronic catabolic conditions;
• Reduces muscle damage markers, improves recovery and, in specific protocols, supports higher gains in lean mass and strength in resistance- and endurance-trained athletes.

“Beyond whey” conceptual position

A conceptual comparison is presented between 25 g of whey protein and a typical MYOHMB-FA™ dose, highlighting:

• Anabolic trigger via HMB as the active metabolite, as opposed to relying only on leucine content in whole protein;
• A direct anticatabolic mechanism through modulation of proteolytic pathways;
• Lower volume, absence of lactose, and more convenient formats versus large-volume shakes;
• Lower caloric load per effective dose.

3. Technological concept

Core physicochemical features

According to the dossier, HMB-FA:

• Is chemically defined as 3-hydroxy-3-methylbutanoic acid, with a small, hydrophilic structure;
• Shows high ionization and good solubility at physiological pH;
• Has moderate hygroscopicity, requiring appropriate moisture control in processing and storage;
• Presents a stability profile compatible with solid forms of rapid dissolution and small-volume liquid solutions, provided that process and packaging are aligned with the stability profile.

These characteristics support the development of solid and liquid nutraceutical forms with controlled quality.

Delivery strategy and dosage forms

The delivery strategy targets a pharmacokinetic profile where:

• Effective plasma HMB levels are reached approximately 30–60 minutes after ingestion;
• The HMB peak is aligned with periods of highest anabolic sensitivity of muscle (peri-workout or around protein-rich meals).

Proposed dosage forms in the dossier include:

• Liquid shot: small-volume aqueous solution;
• Capsules: solid form for daily and peri-workout routines;
• Instant powder: sachets for flexible home use and reconstitution.

API and finished product engineering (high level)

At a non-confidential level, the dossier describes:

• Industrial routes for producing HMB-FA from leucine/KIC or C5 blocks with controlled introduction of the hydroxyl and tertiary methyl group;
• A specification framework for HMB-FA as an API, including assay, impurity profile and microbiological quality compatible with supplement use;
• Base processes for capsules/powders and liquid shots, with in-process controls, dissolution/disintegration targets and analytical methods (identity, assay, impurities and performance) aligned with international guidelines.

4. Potential positioning axes for the product

Based on the clinical and mechanistic synthesis, MYOHMB-FA™ supports different positioning axes for a single product or line, depending on strategy and regulatory context.

Table 2 – Example positioning axes

5. Differentiators versus conventional protein supplementation

Mechanistic clarity
Combined anabolic (MPS) and anticatabolic (reduced proteolysis) actions supported by defined molecular pathways.

High functional density per gram
Ability to deliver the anabolic/anticatabolic trigger in a small dose and low volume, compared with typical protein serving sizes.

Convenience and tolerance
Small-volume shots or capsules, without lactose and with potentially more favorable gastrointestinal profile than high-volume shakes.

Clinical and practical integration
Compatibility with structured training programs and with nutritional strategies aimed at preserving or increasing muscle mass in older adults and selected clinical populations.

6. Structure of the technical program

The MYOHMB-FA™ dossier is organized as a structured program that can be used as a technical backbone for development.

Table 3 – Main components of the MYOHMB-FA™ technical program

7. Intended regulatory classification

According to the dossier, the most appropriate framing for MYOHMB-FA™ is:

• Food supplement for adults and/or athletes;
• Respecting local positive lists, maximum intake limits and standard warnings for the category;
• Using structural and functional claims only, without therapeutic indications, supported by meta-analyses and position stands on HMB.

Examples of conservative claims (to be adapted to local regulations) include:

• Providing HMB, a leucine metabolite used in nutritional strategies associated with strength exercise and adequate protein intake;
• Nutritional support for maintenance of muscle mass when associated with exercise and a balanced diet.

8. Professional statement on use and development

MYOHMB-FA™ is presented as a development asset intended for qualified technical teams in:

• R&D and formulation,
• Quality and CMC,
• Clinical and regulatory affairs,
• Sports and clinical nutrition.

From the dossier perspective, moving from concept to product involves, under the responsibility of the company’s technical team:

• Defining dosage form and final composition;
• Conducting compatibility, stability and performance studies;
• Validating analytical methods and setting specifications;
• Planning regulatory submissions according to the chosen category and markets;
• When relevant, executing pilot and longer-term clinical studies aligned with the positioning strategy.

The asset is not intended for direct use by end consumers and does not, by itself, constitute a finished product. It provides a scientific and technological framework to accelerate the design, evaluation and launch of a product based on MYOHMB-FA™, while maintaining technical consistency with the evidence and the regulatory boundaries for food supplements.